Biomarkers in advanced larynx cancer
dc.contributor.author | Bradford, Carol R. | en_US |
dc.contributor.author | Kumar, Bhavna | en_US |
dc.contributor.author | Bellile, Emily | en_US |
dc.contributor.author | Lee, Julia | en_US |
dc.contributor.author | Taylor, Jeremy | en_US |
dc.contributor.author | D'Silva, Nisha | en_US |
dc.contributor.author | Cordell, Kitrina | en_US |
dc.contributor.author | Kleer, Celina | en_US |
dc.contributor.author | Kupfer, Robbi | en_US |
dc.contributor.author | Kumar, Pawan | en_US |
dc.contributor.author | Urba, Susan | en_US |
dc.contributor.author | Worden, Francis | en_US |
dc.contributor.author | Eisbruch, Avraham | en_US |
dc.contributor.author | Wolf, Gregory T. | en_US |
dc.contributor.author | Teknos, Theodoros N. | en_US |
dc.contributor.author | Prince, Mark E.P. | en_US |
dc.contributor.author | Chepeha, Douglas B. | en_US |
dc.contributor.author | Hogikyan, Norman D. | en_US |
dc.contributor.author | Moyer, Jeffrey S. | en_US |
dc.contributor.author | Carey, Thomas E. | en_US |
dc.date.accessioned | 2014-01-08T20:34:19Z | |
dc.date.available | 2015-03-02T14:35:34Z | en_US |
dc.date.issued | 2014-01 | en_US |
dc.identifier.citation | Bradford, Carol R.; Kumar, Bhavna; Bellile, Emily; Lee, Julia; Taylor, Jeremy; D'Silva, Nisha; Cordell, Kitrina; Kleer, Celina; Kupfer, Robbi; Kumar, Pawan; Urba, Susan; Worden, Francis; Eisbruch, Avraham; Wolf, Gregory T.; Teknos, Theodoros N.; Prince, Mark E.P.; Chepeha, Douglas B.; Hogikyan, Norman D.; Moyer, Jeffrey S.; Carey, Thomas E. (2014). "Biomarkers in advanced larynx cancer." The Laryngoscope 124(1): 179-187. | en_US |
dc.identifier.issn | 0023-852X | en_US |
dc.identifier.issn | 1531-4995 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/102058 | |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | P53 | en_US |
dc.subject.other | Laryngeal Cancer or Carcinoma | en_US |
dc.subject.other | Biomarkers | en_US |
dc.subject.other | EGFR | en_US |
dc.subject.other | Cyclin D1 | en_US |
dc.title | Biomarkers in advanced larynx cancer | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Otolaryngology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/102058/1/lary24245.pdf | |
dc.identifier.doi | 10.1002/lary.24245 | en_US |
dc.identifier.source | The Laryngoscope | en_US |
dc.identifier.citedreference | Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350 – 7356. | en_US |
dc.identifier.citedreference | Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010; 60: 277 – 300. doi: 10.3322/caac.20073. Epub 2010. | en_US |
dc.identifier.citedreference | Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991; 324: 1685 – 1690. | en_US |
dc.identifier.citedreference | Urba S, Wolf GT. Organ preservation in multimodality therapy of head and neck cancer. Hematol Oncol Clin North Am 1991; 5: 713 – 724. | en_US |
dc.identifier.citedreference | Urba S, Wolf G, Eisbruch A, et al. Single‐cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol 2006; 24: 593 – 598. | en_US |
dc.identifier.citedreference | van Oijen MG, Slootweg PJ. Gain‐of‐function mutations in the tumor suppressor gene p53. Clin Cancer Res 2000; 6: 2138 – 2145. | en_US |
dc.identifier.citedreference | Villunger A, Michalak EM, Coultas L, et al. p53‐ and drug‐induced apoptotic responses mediated by BH3‐only proteins puma and noxa. Science 2003; 302: 1036 – 1038. | en_US |
dc.identifier.citedreference | Reed JC, Miyashita T, Takayama S, et al. BCL‐2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996; 60: 23 – 32. | en_US |
dc.identifier.citedreference | Chao DT, Korsmeyer SJ. BCL‐2 family: regulators of cell death. Annu Rev Immunol 1998; 16: 395 – 419. | en_US |
dc.identifier.citedreference | Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of bcl‐xL can confer a multidrug resistance phenotype. Blood 1995; 86: 1903 – 1910. | en_US |
dc.identifier.citedreference | Willis SN, Adams JM. Life in the balance: how BH3‐only proteins induce apoptosis. Curr Opin Cell Biol 2005; 17: 617 – 625. | en_US |
dc.identifier.citedreference | Trask DK, Wolf GT, Bradford CR, et al. Expression of Bcl‐2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation. Laryngoscope 2002; 112: 638 – 644. | en_US |
dc.identifier.citedreference | Adams JM, Cory S. The Bcl‐2 protein family: arbiters of cell survival. Science 1998; 281: 1322 – 1326. | en_US |
dc.identifier.citedreference | Kristiansen G, Denkert C, Schluns K, Dahl E, Pilarsky C, Hauptmann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 2002; 161: 1215 – 1221. | en_US |
dc.identifier.citedreference | Weichert W, Denkert C, Burkhardt M, et al. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res 2005; 11: 6574 – 6581. | en_US |
dc.identifier.citedreference | Kristiansen G, Pilarsky C, Pervan J, et al. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 2004; 58: 183 – 192. | en_US |
dc.identifier.citedreference | Kristiansen G, Schluns K, Yongwei Y, Denkert C, Dietel M, Petersen I. CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer 2003; 88: 231 – 236. | en_US |
dc.identifier.citedreference | Kristiansen G, Winzer KJ, Mayordomo E, et al. CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 2003; 9: 4906 – 4913. | en_US |
dc.identifier.citedreference | Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl‐xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008; 26: 3128 – 3137. | en_US |
dc.identifier.citedreference | Maurizi M, Almadori G, Ferrandina G, et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 1996; 74: 1253 – 1257. | en_US |
dc.identifier.citedreference | Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307 – 310. | en_US |
dc.identifier.citedreference | Piette J, Neel H, Marechal V. Mdm2: keeping p53 under control. Oncogene 1997; 15: 1001 – 1010. | en_US |
dc.identifier.citedreference | Prives C. Signaling to p53: breaking the MDM2‐p53 circuit. Cell 1998; 95: 5 – 8. | en_US |
dc.identifier.citedreference | Leu JI, Dumont P, Hafey M, Murphy ME, George DL. Mitochondrial p53 activates Bak and causes disruption of a Bak‐Mcl1 complex. Nat Cell Biol 2004; 6: 443 – 450. | en_US |
dc.identifier.citedreference | Ondrey FG, Dong G, Sunwoo J, et al. Constitutive activation of transcription factors NF‐(kappa)B, AP‐1, and NF‐IL6 in human head and neck squamous cell carcinoma cell lines that express pro‐inflammatory and pro‐angiogenic cytokines. Mol Carcinog 1999; 26: 119 – 129. | en_US |
dc.identifier.citedreference | Kleer CG, Griffith KA, Sabel MS, et al. RhoC‐GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat 2005; 93: 101 – 110. | en_US |
dc.identifier.citedreference | Islam M, Lin G, Brenner JC, et al. RhoC expression and head and neck cancer metastasis. Mol Cancer Res 2009; 7: 1771 – 1780. | en_US |
dc.identifier.citedreference | Boone B, Van Gele M, Lambert J, Haspeslagh M, Brochez L. The role of RhoC in growth and metastatic capacity of melanoma. J Cutan Pathol 2009; 36: 629 – 636. | en_US |
dc.identifier.citedreference | Xu JH, Wang AX, Huang HZ, Wang JG, Pan CB, Zhang B. Survivin shRNA induces caspase‐3‐dependent apoptosis and enhances cisplatin sensitivity in squamous cell carcinoma of the tongue. Oncol Res 2010; 18: 377 – 385. | en_US |
dc.identifier.citedreference | Kleer CG, Teknos TN, Islam M, et al. RhoC GTPase expression as a potential marker of lymph node metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res 2006; 12: 4485 – 4490. | en_US |
dc.identifier.citedreference | Spiro RH, Guillamondegui O Jr, Paulino AF, Huvos AG. Pattern of invasion and margin assessment in patients with oral tongue cancer. Head Neck 1999; 21: 408 – 413. | en_US |
dc.identifier.citedreference | Carey VJ. Using hypertext and the Internet for structure and management of observational studies. Stat Med 1997; 16: 1667 – 1682. | en_US |
dc.identifier.citedreference | Duffey DC, Chen Z, Dong G, et al. Expression of a dominant‐negative mutant inhibitor‐kappaBalpha of nuclear factor‐kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 1999; 59: 3468 – 3474. | en_US |
dc.identifier.citedreference | Dong G, Chen Z, Kato T, Van Waes C. The host environment promotes the constitutive activation of nuclear factor‐kappaB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. Cancer Res 1999; 59: 3495 – 3504. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.